This astrocytic tumor is classified as a World Health Organization grade I tumor and is often curable. (Refer to the Pilocytic Astrocytoma section in the Classification section of this summary for more information.)
For more information, U.S. residents may call the National Cancer Institute's (NCI's) Cancer Information Service toll-free at 1-800-4-CANCER (1-800-422-6237) Monday through Friday from 8:00 a.m. to 8:00 p.m., Eastern Time. A trained Cancer Information Specialist is available to answer your questions.
The NCI's LiveHelp® online chat service provides Internet users with the ability to chat online with an Information Specialist. The...
Surgery followed by radiation therapy to known or suspected residual tumor.
Treatment options under clinical evaluation:
At recurrence following surgery, patients should be considered for reoperation and radiation therapy if not previously given. Patients who have received radiation therapy should be considered candidates for nitrosourea-based chemotherapies, for temozolomide, or for clinical trials that evaluate new drugs and biological response modifiers.
Current Clinical Trials
Check for U.S. clinical trials from NCI's list of cancer clinical trials that are now accepting patients with adult pilocytic astrocytoma. The list of clinical trials can be further narrowed by location, drug, intervention, and other criteria.
General information about clinical trials is also available from the NCI Web site.
Wallner KE, Gonzales MF, Edwards MS, et al.: Treatment results of juvenile pilocytic astrocytoma. J Neurosurg 69 (2): 171-6, 1988.
Shaw EG, Daumas-Duport C, Scheithauer BW, et al.: Radiation therapy in the management of low-grade supratentorial astrocytomas. J Neurosurg 70 (6): 853-61, 1989.
Stüer C, Vilz B, Majores M, et al.: Frequent recurrence and progression in pilocytic astrocytoma in adults. Cancer 110 (12): 2799-808, 2007.